# EBAMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ebamed

- Industry: Medical Devices & Equipment
- Headquarters: Geneva, Switzerland
- Website: www.eba-med.com
- Total disclosed funding: $19M
- Latest round: Series A (Jan 24, 2025)
- Investors on record: 9

## About

Based in Switzerland, EBAMed SA operates as a medical technology company specializing in innovative non-invasive treatments for heart arrhythmias through advanced external beam ablation techniques.EBAMed SA, founded in 2018, is headquartered in Geneva, Switzerland. The company focuses on developing medical devices that deliver targeted radiation therapy for heart arrhythmias. Adriano Garonna is a key figure in the company's establishment. To date, EBAMed has completed 4 deals, with its latest deal occurring on January 24, 2025, raising EUR 1.6 million in Series A funding from CDP Venture Capital and the European Union, bringing the total amount raised to EUR 1.6 million.EBAMed specializes in the development of innovative medical devices that focus on the non-invasive treatment of heart arrhythmias through the use of external beam ablation techniques powered by radio-therapy. Their core offering is a sophisticated medical device designed to deliver targeted radiation therapy to the heart, addressing the medical need for painless and effective treatment options for patients suffering from arrhythmias. This technology aims to improve patient outcomes by reducing the need for more invasive procedures, thus making it an invaluable solution for healthcare providers. EBAMed targets hospitals and specialized cardiac care centers in various geographical markets, including North America and Europe, where the demand for advanced cardiac care is significant. The end-users of these devices primarily include healthcare professionals in cardiology and patients seeking efficient management of their heart rhythm disorders.EBAMed's revenue model is structured around direct sales of their external beam ablation devices to healthcare institutions, including hospitals and cardiac care facilities. These transactions typically involve comprehensive agreements that may include equipment purchase, maintenance services, and training for medical staff on the operation of the devices. As part of their business transactions, EBAMed may also establish partnerships with healthcare providers to integrate their technology into existing treatment protocols, enhancing the overall patient care experience. While specific pricing plans for their flagship products have not been disclosed, the company employs a competitive pricing strategy to align with the healthcare market's needs and expectations, ensuring accessibility for both large institutions and specialized clinics.In January 2025, EBAMed SA raised EUR 1.6 million in Series A funding from CDP Venture Capital and the European Union. The company will use the funding to develop its non-invasive treatment for patients with heart diseases. Future plans include the introduction of new product lines aimed at further enhancing treatment options for heart conditions, as well as expanding operations into new markets in North America and Europe by the end of 2025.

## Funding rounds

- Series A, Jan 24, 2025, $1.7M — CDP Venture Capital, European Union
- Series A, Jun 27, 2023, $16M — Mayo Clinic, Panakes Partners, European Innovation Council, Efficient Frontier Investing, LIFTT, Occident Group
- Seed, Aug 21, 2019, $1.2M — Fongit Seed Invest

## Investors

- Fongit Seed Invest (https://capitalatlas.ai/funds/fongit-seed-invest) — Seed
- Mayo Clinic — Series A
- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A
- Efficient Frontier Investing (https://capitalatlas.ai/funds/efficient-frontier-investing) — Series A
- LIFTT (https://capitalatlas.ai/funds/liftt) — Series A
- Occident Group — Series A
- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A
- European Union — Series A